Skip to main content

Table 3 The patients’ characteristics at transplantation according to myelofibrosis (n = 141)

From: Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

  MF = 0/1 (n = 121) MF = 2/3 (n = 20) P
Median age of recipient at HSCT (range) 44 (18–66) 42 (27–60) 0.747
Recipient sex 0.511
 Male 70 (57.9%) 10 (50.0%)  
 Female 51 (42.1%) 10 (50.0%)  
Recipient cytogenetic 0.743
 Non-complex karyotypes 102 (84.3%) 16 (80.0%)  
 Complex karyotypes 19 (15.7%) 4 (20.0%)  
BM blasts at HSCT 0.016
  ≤ 5% 29 (24.0%) 10 (50.0%)  
  > 5% 92 (76.0%) 10 (50.0%)  
Time to HSCT from diagnosis 0.529
  ≤ 6 months 87 (71.9%) 13 (65.0%)  
 > 6 months 34 (28.1%) 7 (35.0%)  
Previous therapy for MDS 0.861
 No cytoreductive treatments 57 (47.1%) 9 (45.0%)  
 Cytoreductive treatments 64 (52.9%) 11 (55.0%)  
  HMA 27 (22.3%) 4 (20.0%)  
  Chemotherapy combined with HMA 34 (28.1%) 7 (35%)  
  AML-like chemotherapy 3 (2.5%) 0 (0.0%)  
 Median age of donor (range) 37 (10–63) 40 (26–60) 0.181
Donor sex 0.323
 Male 77 (63.6%) 15 (75.0%)  
 Female 44 (34.2%) 5 (25.0%)  
Donor source 0.838
 HID 51 (42.1%) 8 (40%)  
 MUD 10 (8.3%) 1 (5%)  
 MSD 60 (49.6%) 11 (55%)  
Stem cell source 0.605
 PB 62 (51.2%) 9 (45.0%)  
 PB + BM 59 (48.8%) 11 (55.0%)  
Median mononuclear cells per
graft × 108/kg, (range)
10.2 (7.21–13.9) 10.4 (8.3–14.0) 0.479
Median CD34 + cells per
graft × 106/kg, (range)
9.5 (6.8–13.1) 9.8 (8.1–13.7) 0.246
Conditioning regimens 0.051
 BUCY 56 (46.3%) 3 (15.0%)  
 DAC + BUCY 48 (39.7%) 13 (65.0%)  
 BUCY + others 9 (7.4%) 3 (15.0%)  
 BF 8 (6.6%) 1 (5.0%)  
GVHD prophylaxis 0.870
 CsA + MTX + MMF 60 (49.6%) 11 (55.0%)  
 CsA + MTX + ATG 5 (4.1%) 1 (5.0%)  
 CsA + MTX + ATG + MMF 56 (46.3%) 8 (40.0%)  
  1. BM bone marrow, HID haploidentical donor, MUD matched unrelated donor, MSD HLA-matched sibling donor, PB peripheral blood, BUCY busulfan + cyclophosphamide, DAC decitabine, BF busulfan + fludarabine; GVHD graft-versus-host disease, CsA cyclosporin A, MTX methotrexate, MMF mycophenolate, ATG antithymocyte globulin